- PMID 33911284.
Urwyler S,
Mosbacher J,
Lingenhoehl K, Heid J,
Hofstetter K,
Froestl W, et al. (November 2001). "Positive
allosteric modulation of
native and...
-
Melatonergic Monoaminergic Neurotransmission Opioidergic Serotonergic Froestl,
Wolfgang (2011). "An
historical perspective on
GABAergic drugs". ****ure...
- doi:10.1124/pr.108.00505. PMC 2847512. PMID 18790874.
Bowery NG,
Bettler B,
Froestl W,
Gallagher JP,
Marshall F,
Raiteri M,
Bonner TI, Enna SJ (June 2002)...
-
Treatment Of
Anxiety And Alzheimer's Disease". BioSpace.
Retrieved 2023-03-12.
Froestl, W.; Pfeifer, A.; Muhs, A. (2014). "Cognitive
enhancers (Nootropics). Part...
-
Archived from the
original on 20
March 2022.
Retrieved 15
November 2021.
Froestl W, Muhs A,
Pfeifer A (2012). "Cognitive
enhancers (nootropics). Part 1:...
- self-administration of
nicotine in
animal studies.
Guery S,
Floersheim P,
Kaupmann K,
Froestl W (November 2007). "Syntheses and
optimization of new GS39783 analogues...
- journal}}: CS1 maint:
multiple names:
authors list (link)
Bowery NG,
Bettler B,
Froestl W,
Gallagher JP,
Marshall F,
Raiteri M; et al. (2002). "International Union...
- nicotine.
Urwyler S,
Pozza MF,
Lingenhoehl K,
Mosbacher J,
Lampert C,
Froestl W, et al. (October 2003). "N,N'-Dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4...
- and
neurological disorders therapeutics -
Neuronascent - AdisInsight".
Froestl W, Muhs A,
Pfeifer A (2013). "Cognitive
enhancers (nootropics). Part 2:...
- 37 (2): 181–184. doi:10.1007/BF00558228. PMID 2792173. S2CID 23828250.
Froestl W (2010). "Chemistry and
Pharmacology of
GABAb Receptor Ligands". In Blackburn...
